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ABSTRACT 
The effects of the anticonvulsant drugs diphenylhydantoin and 
phenobarbital on the in vivo incorporation of L- [4 I 5 _3HJ leucine into 
trichloroacetic acid-precipitable rat cerebral cortical protein were inves-
tigated. Protein speCific activities were corrected for differences in 
precursor leucine specific activities. Incorporation was substantially 
depressed following the establishment of plasma concentrations of 
either drug which approximate therapeutic levels in humans. Plasma 
diphenylhydantoin levels of about 10 IJg/ml were associated with a 41% 
depression when radioisotope incorporation was conducted for 5 min; 
phenobarbital concentrations of approximately 28 J.Lg/ml resulted in a 
42% depression following incorporation for the same period. A three-
fold increase in the diphenylhydantoin plasma levels and a six-fold 
increase in the phenobarbital levels were found to invoke little, if any, 
additional effect. The induction period for the diphenylhydantoin effect 
was short (less than 1h), whereas a relative latency was associated with 
the phenobarbital effect. Simultaneous alterations in cortex and plasma 
concentrations of several amino acids were detected, but there appeared 
to be no correlation between these changes and the extent of depression 
of leucine incorporation. Dose-related increases in cortex leucine, 
isoleucine and valine levels occurred following treatment with either 
drug. Cortex glycine concentrations were elevated only in res ponse to 
the largest doses administered. Whereas plasma leucine I isoleucine 
and valine levels were also elevated, no change in plasma glycine con-
centrations were noted following any dose of either drug. The results 
indicate that diphenylhydantoin and phenobarbital inhibit the in vivo 
incorporation of radioactive leucine in the rat cortex when plasma drug 
levels have been attained that are therapeutically rational in the human; 
and substantial inhibitions would probably occur following much lower 
doses in the rat. The relationship of the altered amino acid levels to 
the effects on protein metabolism remains uncertain. 
vii 
INTRODUCTION 
The involvement of protein synthesis as an integral process 
regulating the functional state of the nervous system is widely recog-
nized. 1- 4 The rate of protein synthesis in the brain is considerably 
greater than in most other organs, and it approximates that in secreting 
glandular tissue. 5,6 The finished protein, however I is destined to be 
utilized and metabolized locally I having no egress to the periphery. 
The most likely explanation for such active protein metabolism concerns 
its involvement in the mechanisms of synaptic transmission. 1 There-
fore I the functional state of the nervous system should be especially 
sensitive to agents which modify brain protein synthesis. The purpose 
of the present study was to evaluate the effects of the anticonvulsants 
dipheny lhydantoin and phenobarbital on the in vivo incorporation of 
radioacti ve leucine into rat cerebral cortical (total) protein. Protein 
specific activities were adjusted for differences in the precursor specific 
acti vity . Since fluctuations in the pool size of various amino acids 
have been strongly implicated in alterations of cerebral protein synthe-
sis I 7 1 8 additional information was sought concerning changes in cere-
bral amino acid levels associated with the various treatment schedules. 
The concurrent evaluation of diphenylhydantoin and phenobarbital 
was of interest because the two drugs have extensive application in the 
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therapy of grand mal type seizures, and a similarity with respect to 
their effects on cerebral protein metabolism could have practical, as 
well as functional significance. Although a diphenylhydantoin-induced 
depression of cerebral protein synthesis has already been characterized 
in incubated tis sue s lice pre parations ,9-11 in vivo experiments have 
not been reported. The barbiturates have been shown to inhibit protein 
synthesis in numerous systems, 12-15 but no information is available on 
the effects of phenobarbital on cerebral protein synthesis in vivo. In 
vivo techniques avoid many of the uncertainties associated with the 
interpretation of data obtained from studies vitro (e. g., the duplica-
tion of the complex aqueous environment, diffusion problems in cortical 
slices, etc.). The results indicate that both drugs, in therapeutic con-
centrations I inhibit the 
the rat cortex. 
vivo incorporation of radioactive leucine in 
MATERIALS AND METHODS 
General experimental procedures. Male Sprague-Dawley rats, 
28-30 days old (weight range: 90-100 g), were used in all experiments. 
Animals for both the drug-treatment and control groups within a given 
experiment were obtained simultaneously and kept in a room equipped 
with a diurnal lighting system, having free access to standard rat food 
and water. The sodium salts of diphenylhydantoin (Sigma Chemical Co.) 
and phenobarbital (Parke, Davis & Co.) were prepared fresh daily in 
aqueous 10% gum arabic, the control solution. 
Each experiment consisted of a control group, a diphenylhydantoin-
treated group and a phenobarbital-treated group. Animals received intra-
peritoneal injections according to one of three schedules: Schedule I 
animals received a single 100 mg/kg dose. Schedule II animals received 
three 100 mg/kg doses at twelve hour intervals. Schedule III animals 
received three injections at twelve hour intervals; diphenylhydantoin was 
administered in 100 I 50 and 50 mg/kg doses and phenobarbital was 
administered in 50, 25 and 25 mg/kg doses. Plasma drug levels were 
determined by gas liquid chromatography. 16 
One hour following a single dose (Schedule I) or two hours following 
the last of a multiple dose (Schedules II and III) each animal received 
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intravenously 200 I-LCi/kg* of L-[4,S_3 H] leucine (ICN Isotope and 
Nuclear Division, specific radioactivity 47.6 Ci/mmol) in isotonic 
saline. The injections were made with a 100 I-L l/syringe via the right 
jugular vein while the animals were under light ether anesthesia. Radio-
isotope purity was routinely evaluated by paper chromatography using 
a butanol-acetic acid-water (4:1:1, by vol.) solvent system and What-
man number 41 paper. At various times following the radiois otope 
injection, the rats were sacrificed for subsequent biochemical analyses .. 
Measurement of radioactivity. Most samples, regardless of 
protein content, were prepared for counting with the UnisoI, Unisol-
Complement (Isolab Inc .. ) tissue solubilization system. (Exceptions are 
the effluent fractions collected from the amino acid analyzer; these 
were dissolved in Handifluor, a product of Mallinckrodt Chemical Works .. ) 
The radioactivity was measured with a Nuclear-Chicago PDS/3-ISOCAP/ 
300 liquid scintillation data reduction system.. Efficiency-quench 
correlation was accomplished by the external standard ratio method .. 
Counting effi ciency was 35 -4 0 percent and the c. p .. m. were converted 
to d. p. m. using a suitable program for the PDS/3 computer. Samples 
were counted until the statistical uncertainty associated with the d.p.m. 
was less than 2 percent .. 
*Animals for Schedule III experiments and leucine specific 
activity experiments were administered 560 /1 Ci/kg of L-[4 I 5-3H] 
leucine .. 
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Protein specific activity. Prior to decapitation, each animal was 
anesthetized lightly with ether and exanguinated with a heparinized 
syringe via the dorsal aorta. Upon decapitation the brain was removed 
and the cerebral cortices were dissected free on a cold plate I weighed 
and homogenized at 0-40 C in 10 ml of O. 1 M Tris buffer I pH 7 . 5. 
Aliquots of cortical homogenate were treated with equal volumes of cold 
10% (w/v) trichloroacetic acid (TCA) and centrifuged. The acid-soluble 
supernatants thus obtained were analyzed for radioactivity. The TCA-
insoluble fractions were collected under vacuum on 'Whatman glass 
fiber paper (GF /C grade, 2.4 cm diameter). The precipitates were 
was.hed on the filter three times with cold 5% TCA, extracted twice 
with ethanol-ether (1:1, by vol.) and once with ether. Each wash and 
extraction was accomplished by gentle shaking for ten minutes in an 
Erlenmeyer flask containing 5 ml of the appropriate solvent. The samples 
were then dried under an infrared lamp I transferred to a scintillation 
vial and processed for counting as described above. 
The methanol solubility of TCA-precipitated liver proteins has 
been cited as a potential source of error when the precipitates are 
washed with this solvent .17 However I a series of experiments designed 
to evaluate the magnitude of such a loss in the present system revealed 
Virtually no decrement in the radioactivity associated with the TCA-
precipitated cerebral proteins. (These data are not presented.) 
The cortical homogenates were sampled directly for protein deter-
mination according to the method of Lowry et al. I8 with bovine serum 
albumin as a standard. The reagents used in the above method were 
modified, however, as described elsewhere .19 Protein was collected 
(GF/C glass fiber discs, 10 mm diameter) and processed as described 
above for radioactivity determinations. Results were expressed as 
d. p. m. per milligram of prote in. 
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Amino acid analyses and leucine specific activity. Plasma and 
cerebral cortical tissues were processed for amino acid extraction 
according to the perchloric acid procedure described by Saifer. 2 0 The 
amino acid analyses were performed with a Beckman Model 121 amino 
acid analyzer, employing a single column and a programmed elution 
sequence designed to exclude resolution of the basic amino acids. The 
sodium citrate buffer elution procedure21 employed failed to resolve 
adequately many of the acidic amino acids and their derivatives (partic-
ularly in the threonine to glutamic acid region of the chromatogram). 
Considerable improvement of resolution in this region has been claimed 
by others using a lithium citrate buffer gradient. 22 Amino acid concen-
trations were expressed as micromoles per gram wet weight of cortex or 
per ml of plasma. The radioactivity in leucine and its metabolites was 
determined by collecting the column effluent at two minute intervals and 
analyzing for radioactivity as described above. Specific activities were 
expressed as d.p.m. per micromole amino acid. 
Relative protein specific activity. Relative specific activities 
. were derived by dividing the uncorrected values by the corres ponding 
free leucine specific acti vi ties. 23 
7 
Statistical analysis. Differences between control and experimen-
tal groups of animals were analyzed by one-way analysis of variance 
or the studentized range test. 24 
RESULTS 
The plasma concentrations of diphenylhydantoin and phenobarbital 
at various times following intraperitoneal inj ection are presented in 
Table 1 for the specified treatment schedules. The plasma diphenyl-
hydantoin levels following a single 100 mg/kg inj ection (Schedule 1) 
resemble closely the blood levels reported by Lee and Bass25 following 
the same dosage. Substantial variability was observed in diphenyl-
hydantOin concentrations following the administration of identical doses, 
particularly for the "chronic" high dose experiments (Schedule II). 
The overt symptoms of neurotoxicity (ataxia, graded on an arbitrary 
scale), which became apparent when plasma concentrations exceeded 
approximately 15 J..Lg/ml, were also characterized by a large variability 
within a given treatment schedule. (These data are not presented.) 
Phenobarbital plasma concentrations were much less variable, as were 
the overt symptoms of toxicity. Although Schedule I phenobarbital 
levels are clearly within a range compatible with the comatose state 
in humans, 26 the majority of rats used in these experiments were 
arousable upon stimulation. Schedule II levels, however, were consis-
tent with a uniform production of coma. No overt symptoms of toxicity 
were associated with Schedule III plasma levels at the time of measure-
ment. 
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The therapeutic serum diphenylhydantoin concentration in humans 
is probably between 15 and 20 fl g/ml; intoxication (ataxia I nystagmus I 
etc.) becomes frequent wi th concentrations greater than about 30 f.l g/m1.2 7 
Control of seizures with phenobarbital is generally thought to require 
serum concentrations greater than 10 fl g/ml. Toxicity is usually not 
apparent at levels below 30 flg/ml and much higher levels have been 
compatible with a clear sensorium. 26 Thus I the diphenylhydantoin 
concentrations following Schedules I and III experiments were in a range 
clearly consistent with a therapeutic level in humans I whereas following 
Schedule II treatments the plasma levels approached the range of mini-
mal toxicity. The phenobarbital plasma levels were in a therapeutic 
range only following Schedule III treatments; Schedules I and II levels 
would produce variably light or deep coma I respectively in humans. 
The acute (Schedule I) effects of diphenylhydantoin and pheno-
barbital on the specific activity (dpm/mg protein) of total cerebral 
cortical protein I uncorrected for differences in the precursor leucine 
speCific activity I are depicted in Fig. 1. Illustrated is the time-
dependent change in protein specific activity following radioisotope 
injection. The very rapid incorporation during the initial 15 minutes I 
and the gradual tapering off thereafter I are characteristic for such mea-
surements in brain. 28 SpeCific activities in the drug-treatment groups 
exceeded those in the control groups when radioisotope incorporation 
was conducted for periods between 15 and 120 minutes. The 1/ chronic" 
(Schedule II) effects illustrated in Fig. 2 I likewise uncorrected for 
differences in the free leucine specific activity I demonstrate an 
approximate reversal of the specific activities in the drug-treatment 
groups relative to the control groups seen in Fig. 1. Concurrent mea-
surements of the cortex TCA-soluble radioactivity (Figs. 3 and 4) 
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showed no such reversal: The drug associated increase in radioactivity 
observed early in the acute experiments persists (and intensifies) in 
the" chronic II experiments. Therefore I although the elevated protein 
specific activities observed acutely following drug treatment (Fig. 1) 
might be due to an elevated free leucine specific activity I the lower 
drug-associated specific activities observed following II chronic" adminis-
tration (Fig. 2) are unlikely due to a decrease in specific activity of 
the pre curs or . 
The relationship between the precursor (free leucine) and product 
(total protein) specific activities was investigated directly by quanti-
tati ve analyses of the perchloric acid -extractable cortical leucine and 
its associated radioactivity (see Materials and Methods). An apparent 
dose-related increase (P<O. 01) in cerebral leucine (J.Lmoles/g wet wt. 
of cortex) associated with Schedules I and II plasma drug levels is 
shown in Table 2. Alth<?ugh the data for Schedule III experiments do 
not significantly differ from one another (P> 0.05) I a similar increase 
is suspected. When concentrations of the individual leucine fractions 
were related to the radioactivity contained therein it was found that the 
specific activities of the amino acid were elevated by both drugs under 
all experimental conditions (Table 3). Thus I a portion of the increase 
11 . 
in the total TCA-soluble radioactivity depicted in Figs. 3 and 4 might 
be due to whatever mechanisms are responsible for elevating cerebral 
leucine levels (Vide infra); however, there is a net increase in the ratio 
of radioactive leucine to the unlabelled amino acid. The increase in 
free leucine specific activity was consistently greater than the increase 
in protein specific activity. Therefore, the elevated protein specific 
activities illustrated in Fig. I are a consequence of an elevated free 
leucine specific activity, whereas the lower drug-as sociated specific 
activities displayed in Fig. 2 are, in fact, overestimates of the actual 
values. 
Numerical values for the uncorrected protein specific activities 
depicted in Figs. 1 and 2 are presented for the 5 and 15 minute incor-
poration periods in the upper half of Table 4. Also shown are the spe-
cific activities for Schedule III experiments where incorporation was con-
ducted for 7 . 5 and 15 minutes. The lower half of Table 4 contains data 
derived by dividing the uncorrected values by the average of the cor-
responding leucine specific activities in Table 3. 23 These corrected 
(relative) protein specific activities were consistently lower in the drug-
treatment groups than in the control groups. The maximum diphenyl-
hydantoin-induced depressions associated with the various treatment 
schedules were quantitatively similar despite as much as a three-fold 
difference in plasma drug levels (Tables I and 4). The inhibition by 
phenobarbital also appeared to be fairly insensitive to dose, since an 
approXimate six-fold increase in plasma drug concentrations was 
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associated with a relatively small increment of effect (Schedules II and 
III). It is likely, therefore, that the observed effects approximate the 
efficacy of either drug as an inhibitor of cerebral protein synthesis. 
Experiments with lower doses are clearly warranted to establish a dose-
response relationship. 
Patel and Balazs29 have shown that an injected dose of radio-
labelled leucine is extensively metabolized in brain tissue proper. 
Consequently, a general inhibition of cerebral protein synthesis should 
be consistent with the potential for inhibiting cerebral leucine metab-
olism. To evaluate this hypothesis the radioactivity contained in the 
leucine fraction of the column effluent (see Materials and Methods) was 
expressed as a percentage of the total effluent radioactivity. Such data 
are presented in Table 5 for one to three determinations per experi-
mental group. The apparent depres sion in leucine metabolism seems 
to correlate with the extent to which the incorporation of L-[4, 5-3H] 
leucine into cerebral protein was depressed. For example, approximate-
ly 26% of the radioactivity remained in leucine in cerebral extracts from 
animals receiving control inj ections (Schedule I I 5 minute incorporation); 
an average 35% remained in leucine in animals where incorporation was 
depressed approximately 19% (phenobarbital) I and an average 44% 
remained in the amino acid when incorporation was depressed approxi-
mately 38% (diphenylhydantoin). 
By 15 minutes metabolites accounted for approximately 91 % of the 
total acid -soluble radioacti vi ty in control groups (Table 5). This is in 
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close agreement with the data of Banker and Cotman30 which indicated 
a 94-95% metabolism in 16 minutes. The major radioactive metabolite 
e lu ted with the taurine -urea fractions and, as poi nted out by Banker 
and Cotman, 30 appears to be tritiated water. Substantial radioactivity 
was also found associated with the dicarboxyHc amino acids (especially 
glutamic acid) and their deri vati ves. It is unlikely, however I that 
significant quantitites of these labelled metabolites found their way 
into protein since their specific activities were relatively low. (This 
is because the major dicarboxylic amino acids and derivatives thereof 
are present in exceptionally high concentrations in the brain.) The data 
reported by Roberts and Morelos 31 seem to bear this out: The radio-
activity in a protein hydrolysate obtained 15 minutes after the injection 
of L-[U_14C] leucine resided almost exclusively in leucine. 
As already described, both diphenylhydantoin and phenobarbital 
appear to elevate cerebral leucine levels (Table 2). The concentrations 
of several other amino acids in the cerebral cortex of animals variably 
treated are presented in Table 6. The response of cerebral isoleucine 
and valine levels to drug treatment paralleled the leucine res ponse; i. e. , 
both drugs appeared to elevate both amino acids in the cerebral cortex. 
Glycine levels were elevated by both drugs following Schedule II treat-
ments (P<O. 01) I but no change was apparent at lower plasma drug 
levels. The alanine response was not uniform between the various 
treatment schedules. A Significant increase (P<O.Ol) in cerebral ala-
nine occurred following a single 100 mg/kg dose of diphenylhydantoin 
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(Schedule I) I whereas following three such doses (Schedule II) cerebral 
alanine levels appeared to be lower than controls (P<O. 05). Lower 
alanine levels (P<O. 01) were also found following Schedule III diphenyl-
hydantoin treatments. On the other hand, phenobarbital appeared to 
lower cerebral alanine levels regardless of the particular treatment 
schedule. Vary large doses of phenobarbital might be responsible for 
a small elevation in cortex phenylalanine (P< 0.05, Schedule II). Like-
wise I methionine levels appear to be elevated by high plasma pheno-
barbital levels (P< 0.05) . 
The alterations in plasma free amino acid levels did not uniformly 
parallel those in the cerebral cortex (Tables 2 and 6). Plasma leucine 
levels were significantly elevated following Schedule II diphenylhydan-
toin (P<O. 01) and phenobarbital (P<O. 05) treatments; changes following 
Schedule I experiments are less certain, and Schedule III plasma amino 
acid levels were not determined. The response of plasma isoleucine 
and valine levels to drug treatment was similar to the leucine response: 
As in the cerebral cortex, plasma levels of both amino acids appeared 
to be elevated by both drugs. Plasma glycine levels remained constant 
(unlike the cerebral levels) even following Schedule II treatments. 
The alanine response was again not uniform between the various treat-
ment schedules. Plasma alanine levels might have increased slightly 
following a single injection of diphenylhydantoin (Schedule 1) I but 
II chronic" administration (Schedule II) was associated with a significant 
decrease (P <0.05) . Plasma alanine concentrations were lower following 
15 
phenobarbital treatment regardless of the particular treatment schedule. 
High doses of diphenylhydantoin appear responsible for a small rise in 
plasma phenylalanine levels (P<O. 05 I Schedule II). 
The relative changes in the concentrations of the various amino 
acids in the cortex and in the plasma following drug treatment were 
approximated by the ratio: cerebral amino acid (f.lmoles gram- 1)/plasma 
amino acid (f.lmoles ml-1). This ratio, however, does not necessarily 
reflect the extent of transport, or uptake of the respective amino acid 
into the brain (see Discussion). Schedule I diphenylhydantoin treatment 
appears to be associated with increased cerebral concentrations of 
leucine I isoleucine and glycine relative to the respective plasma con-
centrations i relative cerebral concentrations of alanine, tyrosine and 
phenylalanine were reduced (Tables 2 and 7). The ratios following the 
Schedule II diphenylhydantoin treatment were uniformly lower than for 
the controls, except for the amino acids glycine and alanine. Finally, 
the cortex/plasma amino acid ratios were increased (except for alanine) 
following phenobarbital regardless of the treatment schedule. 
If these ratios were presumed to measure the extent of cerebral 
uptake of the various amino acids, the lower leucine ratio following 
Schedule II diphenylhydantoin treatment would seem to be consistent 
with the lower uptake of radioactive leucine observed in vitro by 
Yanagihara and Hamberger. 1 0 Unlike the in vitro studies, however, 
the present results indicate a net drug-related increase in cerebral 




Protein synthesis is operationally defined for this investigation 
as the incorporation of L-[4, S_3H] leucine into the fraction of the 
cerebral cortex which is precipitated in cold S% TCA. Several assump-
tions are implicit in the interpretation of the data: The rates of protein 
synthesis and degradation are in a steady state during the experimental 
period; no significant recycling of the label occurs; the protein-bound 
radioactivity resides exclusively in leucine; and the drug treatments 
do not alter the subcellular distribution of free leucine in the cortex. 32 
The contribution to error in the first three assumptions is probably 
minimized by experimental design (short incorporation periods and low 
specific activities of leucine metabolites in the brain). It is not possi-
ble at present to estimate the error inherent in the fourth assumption. 
Compartmentalization of free leucine would hinder the equilibration of 
the labelled and the unlabelled molecules; and since computation of 
precursor speCific activities is normally based upon the total extractable 
tissue amino acid, local differences could be overlooked. Thus, the 
observed precursor specific activities might not represent those at the 
actual site of protein synthesis. Problems of interpretation would arise 
in comparative studies if the experimental treatment altered the specific 
activities of the precursor pool in equilibrium with protein synthesis. 
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The present results provide strong evidence that diphenylhydantoin 
and phenobarbital are capable of inhibiting cerebral protein synthesis. 
Maximum depressions (in relative protein specific activities) of approxi-
mately 42% and 63% were observed for the two drugs, respectively 
(Schedule II, Table 4). The induction period for the diphenylhydantoin 
effect is relatively short, since an approximate 38% depression was 
observed in Schedule I only one hour after a single dose. This is con-
sistent with the drug ' s rapid onset of anticonvulsant action (The time 
of peak effect is about 15 minutes in the rat. 33), and is probably related 
to the facility with which it enters the central nervous system (see 
below) . 
The induction period for the phenobarbital effect is comparatively 
longer than that for diphenylhydantoin. An approximate 19% depression 
was observed one hour after a single dose (Schedule I), whereas a 42% 
depression occurred following multiple (Schedule III) dosage when, in 
fact, the plasma drug levels were one-fourth those following the Single 
dose (Tables 1 and 4). The relative latency of the phenobarbital effect 
can likely be explained in terms of two physical properties: the dis-
sociation constant and lipid solubility. Phenobarbital (pka 7.3) is 
only 44.3% unionized at pH 7.4, whereas diphenylhydantoin (pka 8.3) 
is 88.8% unionized at this pH. Furthermore I the lipid solubility (based 
on a chlorobutane/aqueous partitian coefficient) of phenobarbital is 
only 21 % of that of diphenylhydantoin. 34 Since drugs enter the central 
nervous system at rates roughly proportional to (a) the concentration 
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of undissociated molecules at pH 7 . 4 and (b) the lipid-solubility of the 
undissociated molecules, 35 phenobarbital probably attains a steady 
state brain concentration much more slowly than diphenylhydantoin. 
Following II c hronic" diphenylhydantoin treatment similar to 
Schedule II, Yanagihara and Hamberger10 III observed an approximate 
25% inhibition of leucine incorporation in the homogenate fraction in 
studies involving the in vitro incubation of cortical slices. These 
investigators failed to detect a significant inhibition in the homogenate 
fraction when leucine incorporation was evaluated acutely (in a treatment 
program similar to Schedule 1). Studies involving 1/ cell-enriched II 
fractions, however, revealed a prompt and sustained inhibition of incor-
poration in the neuronal fraction I whereas a significant inhibition was 
observed in the glial fraction only after multiple dosage. 11 Thus I the 
above studies revealed changes in the homogenate fraction which ap-
peared to reflect glial rather than neuronal metabolism. 
The results of the present investigation might reflect alterations of 
neuronal as well as glial metabolism. Several investigations have shown 
that brain protein synthesis in the rat is very active at parturition and 
declines continuously thereafter until it reaches a plateau at about 90 
days. 36,37 This decline with age correlates approximately with (a) 
histological evidence for the proliferation of glial cells , 38 (b) with 
increased concentrations of the presumably glial specific S-100 protein,39 
and (c) with increased activities of the enzyme carbonic anhydrase I a 
glial marker. 40 Thus I measurements of protein synthesis in the 
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unfractionated cortex of the adult rat might be expected to involve 
substantial contributions from glial metabolism I since in the mature 
brain the number of glial cells greatly exceed the number of neurons. 38 
Unlike the studies of Yanagihara and Hamberger I however I the present 
investigation was conducted with relatively immature rats I in which 
neurons constitute a greater proportion of the cellular population. 
Therefore I the prompt inhibition of leucine incorporation in the homog-
enate fraction described herein could be due primarily to changes in 
neuronal metabolism. 
Yanagihara and Hamberger10 have proposed that the diphenylhy-
dantoin-induced inhibition may be due partially to a decreased tissue 
uptake of leucine. However I the data presented in this paper reveal 
a net increase in total cerebral free leucine following diphenylhydantoin 
(or phenobarbital) treatment (Table 2). Thus I it appears unlikely that 
the inhibition of cerebral protein synthesis by these drugs is secondary 
to a lower free leucine concentration. 
Nevertheless I studies in vitro7 18 and in vivo31 have indicated 
that protein synthesis in the brain may be unusually sensitive to altera-
tions in the levels of various amino acids. Appel 8 has shown in vitro 
that increasing concentrations of leucine were inhibitory for the incor-
poration of several non -related protein precursors. In addition I leucine 
incorporation was itself inhibited by increasing valine or isoleucine con-
centrations in the incubation medium. This is particularly interesting 
in the context of the present results since I apart from the elevated 
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leucine levels, valine and isoleucine were the only amino acids which 
appeared consistently to be elevated following the various treatment 
schedules (Table 6). Thus, the inhibition by diphenylhydantoin and 
phenobarbital of cerebral protein synthesis in vivo might be due in part 
to higher concentrations of valine and isoleucine. However, it is un-
likely that such an effect can explain the in vitro inhibition described 
by Yanagihara and Hamberger (since the higher brain levels of these 
amino acids are probably secondary to elevated peripheral concentra-
tions; see below). Furthermore, the valine and the isoleucine increases, 
as for leucine, appeared to be dose-related, whereas the effects on 
protein synthesis were not. 
The origin of the elevated cerebral amino acid levels is uncertain. 
Since increases in plasma concentrations also occurred (Tables 2 and 6), 
it is possible that the elevated cerebral levels were secondary to higher 
plasma levels; but, Lajtha and Toth41 have observed that brain levels 
of most amino acids are not altered in response to elevated plasma 
concentrations. Therefore, unless the brain and the plasma levels are 
elevated independently, the mechanism probably involves a specific 
effect on amino acid transport. 
If, for example, drug treatment induced the release of amino acids 
from the liver or muscle, plasma concentrations would undoubtedly 
increase. Brain levels would not be expected to change unless there 
was an accompanying alteration in blood-brain barrier permeability. 
Rapid exchange between plasma and brain free amino acid pools is 
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known to occur for many amino acids ,42 despite the fact that net uptake 
from the blood is usually impeded; and there is evidence that their entry 
and exit from the brain occur by specific mechanisms. 41,43 Since the 
transport of L-leucine I L-isoleucine and L-valine are presumably 
mediated by the same system (the L system proposed by Oxender and 
Christensen43) I the spectrum of changes described presently is consis-
tent with a specific transport effect. The elevated cerebral amino acid 
levels probably result from a stimulation of transport into the brain, 
although an inhibition of transport from cerebrospinal fluid to plasma 
might produce the same result. The present data are not sufficient to 
distinguish between the alternatives. 
Although specific mechanisms have been demonstrated for the 
transport of non-metabolized amino acids from the cerebrospinal fluid 
to plasma, 44 the locus of this process in vivo has not been clarified; 
both the choroid plexus 45 and brain slices46 have been shown to concen-
trate amino acids. Leucine is very rapidly metabolized in the brain 
(this paper and refs 30 and 31) I and if a significant proportion of this 
amino acid is trans ported into the brain I its metabolis m there may inter-
vene with its further transport. The studies of Lajtha and Toth41 did 
not account for this leucine It Sink" effect. Thus I the inhibition of 
cerebral protein synthesis described herein might account for the elevated 
levels of this amino acid by interfering with its metabolism. 
The elevated cerebral glycine levels following Schedule II treat-
ments (Table 6) are probably not related to peripheral effects I since 
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plasma concentrations were unaltered. This is in agreement with avail-
able evidence that cerebral glycine is not derived from the blood I but 
rather from novo synthesis in the cortex. 47 Glycine is apparently 
actively transported into nerve cells from the synaptic cleft (a process 
thought to be involved in the termination of its action at this site). 47 
Since alanine transport is probably mediated by the same system,43 
the low cerebral alanine concentrations following Schedule II drug treat-
ments probably reflect its reciprocal inhibition by glycine. 
It is doubtful that functional significance can be attributed to the 
elevated glycine levels. Although there is strong evidence implicating 
glycine as an inhibitory transmitter in the spinal cord48 and medulla, 49 
a similar role in more rostral parts of the brain seems unlikely. Further-
more I cerebral glycine levels apparently do not change following 
therapeutically more reasonable doses of either drug (Schedules I and 
III I Table 6). 
Van Gelder and co-workers 50 ,51 have correlated regions of 
epileptogenicity in the cortex with substantial increases in glycine 
concentration. Observations that seizure activity is apparently 
associated with an inhibition of protein synthesis in the affected 
tissue 52 I 53 have led these investigators to suggest that the accumu-
lation of glycine in these tissues is due to a diminished re-utilization 
of this amino acid under these circumstances. The apparent refractori-
ness of glycine to metabolic degradation at the synaptic cleft47 might 
contribute to its accumulation. Since particularly high concentrations 
of glycine occur in the more slowly metabolized brain proteins 1 6 the 
elevated levels of this amino acid pos sibl y refle ct inhibition in this 
fraction. 
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Very large doses of diphenylhydantoin can elicit convulsive 
behavior in the rat; and the Schedule II dosage is similar to that to which 
clonic seizure activity has developed. 11 Therefore I the increase in 
cerebral glycine levels following Schedule II drug treatments (Table 6) 
might be related not to the anticonvulsant effects I but rather to the 
convulsive effects of very large doses. Furthermore I whereas the lower 
doses of either drug appear to inhibit primarily the more rapidly metab-
olized proteins (Schedules I and III I 5 minute incorporation I Table 4) t 
the higher plasma levels associated with Schedule II treatments appear to 
inhibit the more slowly metabolized proteins to an equal or greater ex-
tent (15 minute incorporation period t Table 4). On the basi s of these 
data I it seems possible that seizure activity is related to the deficiency 
of a particular protein with a relative long half-life. The inhibition of 
this protein following large doses of either drug could result in the 
accumulation of glycine for the reason noted above. These observations 
might be relevant to the search for a II seizure defense protein. u 54 In 
contrast, the anticonvulsant properties at lower doses might be related 
to the specific inhibition of a more rapidly metabolized protein (see 
below) • 
Another indirect mechanism of inhibition could involve a drug-
induced decrease in available energy. Barbiturates are known to inhibit 
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the respiratory chain in mitochondria, possibly by disrupting the struc-
ture of FAD (see below) .55 Gaitonde and Richter5 have demonstrated an 
inhibition by pentobarbital of the in vivo incorporation of L-[ 358] methio-
nine into rat brain proteins; they suggested that the inhibition may be 
related to the lower oxygen consumption of the brain under such condi-
tions. However I Shuster and Hannan13 have correlated the pentobarbital 
inhibition with the hypothermic response of rodents to this drug. Fur-
thermore, investigation has failed to detect an effect of either diphenyl-
hydantoin or phenobarbital on tissue respiration or glycolysis in incu-
bated brain slices. 56 Thus I a more relevant concern might be the 
possibility of a drug-induced hypothermia. This is especially true for 
the sedative and hypnotic agents, including phenobarbital. 
Diphenylhydantoin and phenobarbital might conceivably alter 
cerebral protein synthesis in a more direct way. Recent work has shown 
that certain hydantoins 57 and barbiturates 58 form highly specific, 
hydrogen-bonded dimers with adenine I or with the adenine moiety of 
FAD and NAD. 55 The affinities of diphenylhydantoin and phenobarbital 
for adenine are both greater than those of uracil and thymine for adenine.59 
Thus, a preferential association of these drugs with the recently dis-
covered poly A-rich segments of a particular messenger RNA might 
effectively interfere with the transcription of protein. 
Direct evidence for such a phenomena I however, is lacking. Kemp 
and Woodbury60 have demonstrated that the microsomal fraction is the 
major binding site for diphenylhydantoin in rat cerebral cortex. 
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Accumulation in this fraction was noted for periods up to 12 hours 
following a single intracisternal injection; and indirect eVidence was 
provided that this accumulation might occur as a result of an interaction 
with membrane-bound ribonucleoprotein. Yanagihara and Hamberger10 
have re ported a prolonged inhibition of leucine incorporation into micro-
s omal proteins following diphenylhydantoin treatment in the rat. Thus, 
diphenylhydantoin accumulates and appears to inhibit protein synthesis 
in those subcellular structures with which the majority of cellular RNA 
is normally associated. 
The hydrogen-bonding affinity of phenobarbital58 for adenine is 
substantially greater than that of diphenylhydantoin57 (with adenine). 
Therefore, if the inhibition of protein synthesis by these drugs is a 
consequence of their hydrogen-bonding affinity for adenine in RNA, 
phenobarbital should presumably be the more potent inhibitor. This was 
not verified by the present results, since approximately equal effects 
. were achieved only when phenobarbital plasma concentrations were 
three-fold greater than the diphenylhydantoin levels (Schedules III, 
Tables 1 and 4); but conclusions based upon these observations are 
complicated without a more complete knowledge of the dose-response 
curves. Furthermore, the actual concentration of phenobarbital at the 
site of action may, according to the principles outlined above for its 
penetration into the brain, be substantially lower than that of diphenyl-
hydantoin. It is probable that the participation of such mechanisms in 
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the inhibition of protein synthesis would be more appropriately evaluated 
in a cell-free system. 
A correlation of the results from the present investigation with a 
relevant (anticonvulsant) alteration of the functional state of the central 
nervous system must remain entirely speculative. Although the average 
half-life of the proteins of rat brain is about 14 days, there is consider-
able variability in this parameter; estimates of the half-lives of individ-
ual components have ranged from seconds to several months. 5,6 
Since the present results are based upon observations of total acid-
precipitable protein, information relating to specific effects on individual 
proteins is obviously lacking. 
Since the most active brain protein metabolism appears to be 
related to synaptic function, 1 metabolic alterations of the proteins 
involved therein might conceivably be the basis for an anticonvulsant 
effect. Especially interesting in this context are certain IIbrain specific" 
proteins with no known enzymatic activity, but for which evidence 
implicating their role in synaptic function is rapidly accruing. These 
are the soluble, acidic proteins whose abundance, high turnover rates 
and unusual physical properties have provoked much investigation .1,61 
The physiological function of these acidic proteins remains un-
certain. However I they appear to serve as integral components of 
transmitter release. They are known to occur in the nerve endings in 
association with the various transmitter substances in storage granules. 
Upon stimulation they are released together with the transmitter into the 
synaptic cleft. Increased frequency of stimulation is presumably 
associated with an enhanced release and turnover of these soluble 
proteins. 1 Thus I an inhibition of protein turnover could conceivably 
interfere with transmitter release. 
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High concentrations of rapidly metabolized soluble protein have 
been detected in areas of the cerebellum known to contain substantial 
quantities of acetylcholine. 61 The reported ability of diphenylhydantoin 
and phenobarbital to inhibit the synthesis of free acetylcholine in brain 
slices 62 might be related to an inhibition of a soluble protein associated 
with its release. However I the involvement of such an inhibition in 
the mediation of an anticonvulsant effect must be considered in relation-
ship to the latency of such an effect. For example I the time of peak 
effect of diphenylhydantoin for protection against maximal electroshock 
is about 15 minutes in rats. 33 Thus I the relevant alterations must occur 
within this time. Although the neuron is a cell with a high capacity for 
protein synthesis I the preponderance of evidence indicates that most 
of the synthesis occurs in the soma. 63 Axoplasmic flow is thought to 
provide the bulk of the distal protein requirements; but the most rapid 
flow rates are probably too slow to account for a distal protein defi-
ciency within 15 minutes of somal inhibition. 64 An effect on local 
(synaptic) synthesis I therefore I may be more consistent with the latency 
of the anticonvulsant effect. 
Although axons and nerve endings do not contain visible ribos omes I 
their capacity to synthesize protein has been demonstrated repeatedly.65 
Austin and Morgan66 have described a substantial non-mitochondrial 
protein synthesis in synaptosomes; at least 75% of the total precursor 
amino acid was found in soluble and non-mitochindrial membrane-
bound proteins. Since the prolonged inhibition by diphenylhydantoin 
of protein synthesis in the synaptosomal fraction appears to correlate 
with the duration of its anticonvulsant effect in rats, 10 further study 
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of the drug's actions on synaptic protein metabolism appears warranted. 
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Fig. 1. The acute (Schedule 1) effects of diphenylhydantoin and pheno-
barbi talon the specific acti vi ty (dpm!mg protein) of the trichloroacetic 
acid-precipitable fraction of rat cerebral cortex measured at various 
times following L-[4, 5-3H] leucine injection. Values are not corrected 
for differences in the precursor leucine specific activity. Each point 
represents the mean of three to six determinations on separate animals. 
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Fig. 2. The chronic (Schedule II) effects of diphenylhydantoin and 
phenobarbi talon the s pe cifi cacti vi ty (dpm/mg prote in) of the tri chloro-
acetic acid-precipitable fraction of rat cerebral cortex measured at 
various times following L-[4, s-3:rn leucine injection. Values are not 
corrected for differences in the precursor leucine specific activity. Each 
point represents the mean of three to six determinations on separate 
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Fig. 3. The acute (Schedule I) effects of diphenylhydantoin and pheno-
barbital on the radioactivity contained in the trichloroacetic acid-
soluble fraction (dpm!g wet wt.) of rat cerebral cortex measured at 
various times following L- [4, S_3H] leucine inj ection. Each point repre-
sents the mean of three to six determinations on separate animals. The 
vertical bars represent the standard errors of the mean. 
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Fig. 4. The chronic (Schedule II) e cts of diphenylhydantoin and 
phenobarbital on the radioactivity contained in the trichloroacetic acid-
soluble fraction (dpm!g wet wt.) of rat cerebral cortex measured at 
various times following L-[4 I S_3HJ leucine injection. Each point repre-
sents the mean of three to six determinations on separate animals. The 
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Table 1. Plasma Drug Levels Following Specified Treatment Schedules 
Diphenylhydantoin (/Jg/mU Phenobarbital U-tg/mU 
Hours Following Final Injection 
Schedule+ 
1 2 3 4 1 2 3 4 
I 17.0.:t0. 7 12.9.:t2.0 16.1±0.6 111.3 ± 3.8 92.8 ± 1.9 82.6 ± 1.0 
II 31.4.:t5.6 27.6±3.9 33.6±0.4 162.0* 1 86 . 2 .:t 4. 4 16 7 • 5 .:t 6. 0 
III 10.2.:t0.5 17.9±0.6 28.2±1.5 29.8.:t0.1 
20 
Plasma drug levels were determined by gas chromatography. Each value represents the mean + S.E.M. of three to 
four determinations on separate animals I except where a single determination is noted (*). -
;Schedule I: Single 100 mg/kg intraperitoneal injection; Schedule II: Three 100 mg/kg intraperitoneal injections at 
12 hour intervals: Schedule III: Three intraperitoneal injections at 12 hour intervals; 100, 50 and 50 mg/kg (diphenyl-
hydantoin) and 50, 25 and 25 mg/kg (phenobarbita 1). 
~ 
w 
Table 2. Effects of Diphenylhydantoin and Phenobarbital on 
Free L-Leucine Levels in Rat Plasma and Cerebral Cortex 
A. Plasma Leucine W moles/mO B. Cerebral Leucine W moles/g) 
Schedule 
Control DPH PB Control DPH PB 
I 0.068.±. 0.009 0.081.±. 0.010 0.059.±. 0.006 0.067.±. 0.002 0.091.±. 0.004 t 0.081.±. 0.003~§ 
II 0.072.±. 0.005 0.147,±, 0.012* 0.104.±. 0.011t§ 0.073.±. 0.007 0.126.±. 0.012+ 0.123.±. 0.013+ 
III 0.055 .±. 0.004 0.067.±. 0.004 0.063.:!:.0.OO9 
B/A* 
Control DPH PB 
0.99 1.12 1.37 
1. 01 0.86 1.18 
Animals were sacrificed for amino acid extraction approximately one hour following a single drug injection (Schedule 1) or 
approximately two hours following the last of three drug injections (Schedules II and III). Extraction and analyUcal procedures 
are described in Materials and Methods. AbbreviaUons: (OPHL diphenylhydantoin; (PB), phenobarb1tal. Each value represents 
the mean + S.E.M. leucine concentration from amino acid analyses of 3-7 extracts involving 4-5 animals per extract. 
*ee-;ebral leucine/plasma leucine. 
tp < 0.05 for comparison of treatment value with control value. 
*p < 0.01 for comparison of treatment value with control value. 




Table 3. Effects of Diphenylhydantoin and Phenobarbital on L-Leucine 
Specific Activity in Rat Plasma and Cerebral Cortex Precursor Pools 
Control Diphenylhydantoin 
Incorporation Period (min) 
Phenobarbi ta I 





























Cortex Specific Activity (dpm/Il mole leucine) 
41129 241980 67022 204240 
51428 298364 91124 233069 
65163 101219 254844 
69542 
45209 243211 78461 319844 
60386 261537 85124 349571 
60746 140794 85238 151446 











Specific activities were measured as described in Materials and Methods. Values 
represent raw data for one to four determinations per experimental group. Plasma specific 
activities for Schedule III experiments were not determined. 
*The incorporation period for Schedule III experiments was 7.5 minutes. 
.r::.. 
c..n 
Table 4. Effects of Diphenylhydantoin and Phenobarbital on Incorporation 
lr!. Vivo of L-[4, 5-3H] Leucine into Rat Cerebral Protein 
Control Diphenylhydantoin Phenobarbital 
Schedule 
5(7.5) 
884 ±. 62 
II 864 ±. 72 
III 3943 .:!::..2SS 
451.±32 
II 469 .± 39 
III 3224 .± 209 
Incorporation Period (min) 
15 5(7.5) 15 5(7.5) 
Specific Activity. Uncorrected (dpm/mg protein) 
1451 ±. 57 751 ±. 36 1666 ±. 74 841 ±. 44 
1403 ±. 29 701 ±. 89 1253 .!. 97 683 ±. 60 
3973±.148 2824 ±. 173 3487.±191 2979 .± 118 
Specific Activity. Corrected (dpm/mg protein) 
2553 .± 100 278.± 13t 1927 ± 8St 364..±..19** 
(38.4) (24.5) (19.3) 
2657 .± 56 278 .± 35t 1532.± 119t 204 .± 1st 
(40.7) (42.3) (56.5) 
6374 .± 238 1915 t.118t 3984 ±. 219t 1863 .± 74t 
(40.6) (37.5) (42.2) 
15 
1560..±.. 48 
1092 ±. 50 
3542.± 143 
2254 .± 70** 
(11.7) 




Specific activities were measured as described in Materials and Methods. Schedule III experiments were 
conducted with an initial isotope radioactivity approximately three times that used in Schedule I and Schedule II 
experiments. The incorporation periods for Schedule III experiments were 7.5 and 15 minutes. The corrected specific 
activities were derived by dividing the uncorrected values by the corresponding leucine specific activities in Table 3. 
Each value represents the mean ±. S.E.M. specific activity determined on three to six animals. The numbers in 
parentheses beneath the corrected specific activities depict the percent depression in that respective value relative 
to its control. 
*p < 0.05 for comparison of treatment va lue with control va lue. 
tp < 0.01 for comparison of treatment value with control value. 
:f:p < 0.05 for comparison of phenobarbital va lue with diphenylhydantoin value. 
§p < 0.01 for comparison of phenobarbital value with diphenylhydantoin va lue. 
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Table 5. Effects of Diphenylhydantoin and Phenobarbital on 
L-[4 I 5-3H] Leucine Metabolism in Rat Cerebral Cortex 
Control Diphenylhydantoin Phenobarbital 
Incorporation Period (min) 
Schedule 
5 (7 . 5) 15 5(7.5) 15 5 (7 .5) 15 
I 23.5 17.1 47.2 21.3 36.3 22.8 
28.3 7.4 46.2 20.1 28.0 14.2 
26.0 7.7 39.8 23.5 39.8 27.0 
II 20. 1 9.2 35. 1 24.6 47.5 22.3 
27.0 6.8 35.0 15.7 41.7 35.0 
III 15.6 7.3 29.4 20.4 38.4 25.0 
19.3 25.2 40.6 
Each value is the percent of the total acid soluble radiqactivity 
remaining in leucine at the specified time. The incorporation periods 
for Schedule III experiments were 7.5 and 15 minutes. Raw data are 
presented for one to three determinations per experimental group~ ~ 
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Table 6. Effects of Diphenylhydantoin and Phenobarbital on Free Amino Acid 
Concentrations in Rat Plasma and Cerebral Cortex 
Plasma Ulmoles/ml) Cerebral Cortex {JJ.moles/gJ 
Schedule 
Amino Acid Control DPH PB Control DPH pa 
I Glycine 0.295.:t 0.042 0.269.:t 0.031 0.256.:t 0.027 0.656 + 0.019 0.644 + 0.017 0.650 + 0.014 
Alanine o . 432 .:t 0 .054 o . 500 .:t 0.058 0.386.:t 0.037 0.969.:t 0.028 1.074.:t 0.032+ 0.834 ~ 0.017+§ 
Valine 0.091.:t 0.013 0.101.:t 0.015 0.084.:t 0.008 0.113.:t 0 . 004 0.129.:t 0.005* 0.133.:t 0.005* 
Methionine 0.018.:t 0.002 o . 018 .:t 0 . 002 0.019.:t 0.003 o .019 .:t 0 . 001 o . 019 .:t 0;002 0.,022.:t 0.001 
Isoleucine 0.046.:t0.007 0.051.:t 0.007 0.042 .:t 0.003 0.046.:t0. 003 0.057.:t 0.002* 0.054.:t 0.002* 
Tyrosine 0.044.:t 0.005 0.047 .:t 0 . 008 o . 045 .:t 0 . 006 0.070 + 0.005 0.065 + 0.005 0.081 + 0.008 
Phenylalanine 0.033.:t 0.001 0.035 .:t 0.005 0.026.:t 0.003 0.042.:t 0.002 0.042 .:t 0.003 0.046.:t 0.002 
II Glycine 0.260.:t0.017 0.254.:t0.019 0.269.:t0.022 0.606 .:t 0.018 O. 791 .:t 0.026 + 0.807.:t0.021+ 
Alanine 0.463.:t 0.031 0.233 + 0.048* 0.390 + 0.061* 0.850.:t 0.019 0".73 1 .:t.0.03S* 0.601 .:t 0.034+* 
Valine 0.086.:t 0.005 0.167~0.01l+ 0.122~0.013** 0.121 .:t. 0.008 0.181.:t 0.016* 0.212 .:t. 0.020 + 
Methionine 0.022.:t 0.001 0.026 + 0.003 0.027 + 0.003 0.025.:t 0.002 0.023.:t 0.002 0.040.:t 0.005** 
Isoleucine o . 041 + O. 003 0.107"+ 0.007+ 0.062"+ 0.008§ 0.044 + 0.004 0.088 + 0.009* 0.084 + 0.012* 
Tyrosine 0.049 + 0.004 0.052 + 0.003 0.048 + 0.003 0.068 + 0.006 O. 067 + O. 002 0.089 + 0.011 
Phenylalanine 0.039 + 0.003 0.056 + 0.004* 0.043 + 0.003* 0.051 + 0.003 0.062 + 0.002 0.069 + 0.006* 
Glycine 0.662.:t 0.036 0.667 + 0.026 0.654.:t 0.042 
Alanine 0.891.:t. 0.017 O. 777 ~ 0.001+ 0.847 .:t. 0.016* 
III 
Valine 0.122.:t 0.005 0.138.:t 0.010 0.129 .:t 0.010 
Methionine 0.015.:t 0.000 0.022.:t 0.002* 0.017.:t 0.002* 
Isoleucine 0.040.:t 0.002 0.045.:t 0.002 0.042.:t 0.002 
Tyrosine 0.065 .:t 0.009 0.064 .:t 0.009 0.073.:t 0.008 
Phenylalanine 0.044 .:t 0 . 003 0.OS6.:t 0.006 0.046.:t 0.002 
Animals were sacrificed for amino acid extraction as described in the legend to Table 2. Each value represents the 
mean.:t. S.E. M. amino acid concentration from analyses of 3-7 extracts involving 4-5 animals per extract. 
*p < 0.05 for comparison of treatment value with control value. 
+P < 0.01 for comparison of treatment value with control value. 
*p < O. OS for comparison of phenobarbital value with diphenylhydantoin value. 
~p < 0.01 for comparison of phenobarbital value with diphenylhydantoin value. 
J::>. 
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Table 7. Effects of Diphenylhydantoin and Phenobarbital on 
Amino Acid UPtake*Into Rat Cerebral Cortex 
Cerebral amino acid (p, moles/g)/Plasma amino acid (p. moles/ml) 
Schedule Amino Acid Control DiEhenylhydantoin P he no ba r b ita I 
I Glycine 2.22 2.39 2.54 
Alanine 2.24 2.15 2.16 
Valine 1.24 1.28 1.58 
Methionine 1.06 1.06 1.16 
Isoleucine 1.00 1 . 12 1.29 
Tyrosine 1.59 1.38 1.80 
Phenylalanine 1.27 1.20 1.77 
II Glycine 2.33 3.11 3.00 
Alanine 1.84 3.14 1.54 
Valine 1.41 1.08 1.74 
Methionine 1.14 0.88 1.48 
Isoleucine 1.07 0.82 1.35 
Tyrosine 1.42 1.29 1.85 
Phenylalanine 1.31 1 . 11 1.60 
The ratios (cerebral amino aCid/plasma amino acid) are constructed from 
the data in Table 6. 
*These ratios may not necessarily reflect the extent of transport, or 
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